Melanocortin Receptor 4 MC4R Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500
Melanocortin Receptor 4 MC4R Pipeline Review, H2 2017
Summary
Melanocortin Receptor 4 MC4R pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocortin Receptor 4 MC4R Pipeline Review, H2 2017, outlays comprehensive information on the Melanocortin Receptor 4 MC4R targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Melanocortin Receptor 4 MC4R Melanocortin 4 receptor MC4R is a G proteincoupled receptor involved in the hypothalamic leptinmelanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 7 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Musculoskeletal Disorders, Women's Health, Genetic Disorders, Genito Urinary System And Sex Hormones, Infectious Disease and Male Health which include indications Obesity, Infantile Spasm West Syndrome, Type 2 Diabetes, Alphavirus Infections, Amyotrophic Lateral Sclerosis, Cachexia, Diabetes, Erectile Dysfunction, Female Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction, Gouty Arthritis Gout, Lipodystrophy, Metabolic Syndrome, Multiple Sclerosis, Nephrotic Syndrome and PraderWilli Syndrome PWS.
Furthermore, this report also reviews key players involved in Melanocortin Receptor 4 MC4R targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 MC4R
The report reviews Melanocortin Receptor 4 MC4R targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Melanocortin Receptor 4 MC4R targeted therapeutics and enlists all their major and minor projects
The report assesses Melanocortin Receptor 4 MC4R targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Melanocortin Receptor 4 MC4R targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 MC4R
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 MC4R development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Original Article: Melanocortin Receptor 4 MC4R Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500
